Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

ConferenceBHV-1530cemiplimabLibtayoPositive

AI Analysis

Summary

Biohaven announces Phase 1 dose-escalation data for BHV-1530, an FGFR3-directed ADC, showing early tumor reductions, and enters a clinical supply agreement with Regeneron to evaluate the drug in combination with cemiplimab. Data will be presented at ESMO Congress.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Phase 1 dose-escalation data showing early tumor reductions presented at ESMO Congress

Importance:6/10

Sentiment:

0.60

ADCFGFR3oncologypartnershipclinical-dataESMOcombination-therapy

Related Companies

$REGN

Read the original article

Published by PR Newswire Pharma on July 20, 2026 11:30 AM

Read Original